Quratis Inc. (KOSDAQ:348080)

South Korea flag South Korea · Delayed Price · Currency is KRW
938.00
+68.00 (7.82%)
Last updated: Aug 8, 2025
7.82%
Market Cap64.26B
Revenue (ttm)1.52B
Net Income (ttm)-24.13B
Shares Out73.86M
EPS (ttm)-489.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume452,853
Average Volume265,555
Open875.00
Previous Close870.00
Day's Range875.00 - 992.00
52-Week Range516.00 - 2,095.00
Beta-0.42
RSI42.57
Earnings Daten/a

About Quratis

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; dendritic cell-based cell therapy for indications, including cancer, autoimmune, and infectious diseases; and peptide nucleic acid-based antimicrobial agents. The company also offers drugs contract development and manufacturing services. Quratis Inc. was founded in 2016 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348080
Full Company Profile

Financial Performance

In 2024, Quratis's revenue was 373.80 million, a decrease of -63.71% compared to the previous year's 1.03 billion. Losses were -26.27 billion, 54.6% more than in 2023.

Financial Statements

News

There is no news available yet.